These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11117485)

  • 1. N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice.
    van Dellen A; Welch J; Dixon RM; Cordery P; York D; Styles P; Blakemore C; Hannan AJ
    Neuroreport; 2000 Nov; 11(17):3751-7. PubMed ID: 11117485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease.
    Menalled L; Zanjani H; MacKenzie L; Koppel A; Carpenter E; Zeitlin S; Chesselet MF
    Exp Neurol; 2000 Apr; 162(2):328-42. PubMed ID: 10739639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice.
    Rajput PS; Kharmate G; Norman M; Liu SH; Sastry BR; Brunicardi CF; Kumar U
    PLoS One; 2011; 6(9):e24467. PubMed ID: 21912697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
    MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
    J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice.
    Kosinski CM; Cha JH; Young AB; Mangiarini L; Bates G; Schiefer J; Schwarz M
    Neuroreport; 1999 Dec; 10(18):3891-6. PubMed ID: 10716229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice.
    Zala D; Bensadoun JC; Pereira de Almeida L; Leavitt BR; Gutekunst CA; Aebischer P; Hayden MR; Déglon N
    Exp Neurol; 2004 Jan; 185(1):26-35. PubMed ID: 14697316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    Ferrante RJ; Andreassen OA; Jenkins BG; Dedeoglu A; Kuemmerle S; Kubilus JK; Kaddurah-Daouk R; Hersch SM; Beal MF
    J Neurosci; 2000 Jun; 20(12):4389-97. PubMed ID: 10844007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease.
    Anzilotti S; Giampà C; Laurenti D; Perrone L; Bernardi G; Melone MA; Fusco FR
    Brain Res Bull; 2012 Feb; 87(2-3):350-8. PubMed ID: 21272617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.
    Bibb JA; Yan Z; Svenningsson P; Snyder GL; Pieribone VA; Horiuchi A; Nairn AC; Messer A; Greengard P
    Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6809-14. PubMed ID: 10829080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum.
    Régulier E; Trottier Y; Perrin V; Aebischer P; Déglon N
    Hum Mol Genet; 2003 Nov; 12(21):2827-36. PubMed ID: 12952868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficiency of Ube3a in Huntington's disease mice brain increases aggregate load and accelerates disease pathology.
    Maheshwari M; Shekhar S; Singh BK; Jamal I; Vatsa N; Kumar V; Sharma A; Jana NR
    Hum Mol Genet; 2014 Dec; 23(23):6235-45. PubMed ID: 25027318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
    Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
    Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.
    Petersén A; Hansson O; Puschban Z; Sapp E; Romero N; Castilho RF; Sulzer D; Rice M; DiFiglia M; Przedborski S; Brundin P
    Eur J Neurosci; 2001 Nov; 14(9):1425-35. PubMed ID: 11722604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
    Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
    J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
    Hansson O; Petersén A; Leist M; Nicotera P; Castilho RF; Brundin P
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8727-32. PubMed ID: 10411943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.
    Denovan-Wright EM; Robertson HA
    Neuroscience; 2000; 98(4):705-13. PubMed ID: 10891614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.